Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced or Refractory Solid Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02595866
What this trial is testing

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Who this might be right for
AIDS-Related Non-Hodgkin LymphomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+16 more
National Cancer Institute (NCI) 58
Early research (Phase 1)Study completedNCT05702424
What this trial is testing

Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

Who this might be right for
Solid Tumor
IGM Biosciences, Inc. 14
Early research (Phase 1)Looking for participantsNCT07306559
What this trial is testing

Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

Who this might be right for
Advanced Relapsed or Refractory Germ Cell TumoursAdvanced Relapsed or Refractory Endometrial CancerAdvanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim 187
Testing effectiveness (Phase 2)Active Not RecruitingNCT03155620
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma+42 more
National Cancer Institute (NCI) 1,377
Early research (Phase 1)Study completedNCT01245205
What this trial is testing

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more
National Cancer Institute (NCI) 28
Early research (Phase 1)Study completedNCT00737555
What this trial is testing

The Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours

Who this might be right for
Solid Tumor
Chroma Therapeutics 23
Early research (Phase 1)Temporarily pausedNCT03722186
What this trial is testing

Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

Who this might be right for
Physiological Effects of DrugsNeoplasms by Histologic TypeLymphoma+3 more
Jiangsu HengRui Medicine Co., Ltd. 128
Early research (Phase 1)Study completedNCT04349969
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104

Who this might be right for
Neoplasms Malignant
Akesobio Australia Pty Ltd 38
Testing effectiveness (Phase 2)Study completedNCT04233567
What this trial is testing

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Who this might be right for
Advanced Malignant Solid NeoplasmCholangiocarcinomaMetastatic Malignant Solid Neoplasm+1 more
Sameek Roychowdhury 17
Early research (Phase 1)Study completedNCT02898207
What this trial is testing

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Who this might be right for
Metastatic High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Malignant Solid NeoplasmMetastatic Primary Peritoneal Serous Adenocarcinoma+16 more
National Cancer Institute (NCI) 28
Early research (Phase 1)Study completedNCT01202032
What this trial is testing

Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors

Who this might be right for
Metastatic Renal Cell CarcinomaAdvanced Refractory Solid Tumors Histologically or Cytologically Confirmed
Centre Leon Berard 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175
What this trial is testing

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT06390826
What this trial is testing

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT02465060
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder Carcinoma+49 more
National Cancer Institute (NCI) 6,452
Early research (Phase 1)Ended earlyNCT01278849
What this trial is testing

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

Who this might be right for
Histologically-proven and Radiologically-confirmed Solid Tumors
Novartis Pharmaceuticals 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT03213704
What this trial is testing

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent EpendymomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor+30 more
National Cancer Institute (NCI) 9
Testing effectiveness (Phase 2)Looking for participantsNCT07189871
What this trial is testing

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Who this might be right for
Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+7 more
Radiopharm Theranostics, Ltd 61
Early research (Phase 1)Study completedNCT03595059
What this trial is testing

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

Who this might be right for
Advanced Solid Tumors
AbbVie 168
Testing effectiveness (Phase 2)Study completedNCT03213665
What this trial is testing

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin Lymphoma+38 more
National Cancer Institute (NCI) 20
Early research (Phase 1)Looking for participantsNCT07800936
What this trial is testing

HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors

Who this might be right for
Solid Tumors
Parr Biotechnology (Hebei) Co., Ltd. 44
Next Page